Enzo Biochem (ENZ) Reports In-Line Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Enzo Biochem Reports Strong First Quarter
December 7, 2015 4:15 PM ESTExecution on Corporate Strategy seen in Companys Results
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE: ENZ) today reported another period of strong results for the first fiscal quarter ended October 31, 2015.
First Quarter Highlights
Strong financial performance at Enzo Clinical Labs and new legal settlements contributes to year-over year revenues and net income gains. Total Revenue was $25.2 million with Clinical Lab Revenue of $17.1 million up 8% over prior year. Gross margins at the Lab climbed to 40%, an increase of 400 basis... More